Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
People with multiple myeloma have a higher chance of getting infections because of the disease and its treatment. Some people who get a multiple myeloma drug called a bispecific monoclonal antibody (BsAb) develop hypogammaglobulinemia. The level of immunoglobulins in their blood is low and the risk of infection is high. Immunoglobulins are proteins made by the immune system to prevent infections.
This study is assessing ABBV-637 and ABBV-155 with ERAS-801 or standard treatment in people with glioblastoma. The people in this study have newly diagnosed glioblastoma or glioblastoma that returned after treatment and can be surgically removed. In addition, their tumors have a mutation (change) in the EGFR gene.
Researchers want to learn if L19IL2 and L19TNF, alone or together, work well to treat melanoma when given with pembrolizumab. The people in this study have melanoma that has metastasized (spread) or is inoperable (cannot be taken out with surgery). Their cancers keep growing even after having immune-boosting therapy.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing the effectiveness of the combination of lenvatinib, pembrolizumab immunotherapy, and fulvestrant to treat advanced breast cancer. The people in this study have inoperable or metastatic breast cancer (cancer that has spread) that is estrogen receptor-positive and HER2-negative.
Researchers want to see how well ivonescimab works as a treatment for endometrial and cervical cancers. The people in this study have endometrial or cervical cancer that keeps growing after treatment.
ARV-393 targets and breaks down a protein called BCL6. This protein is found in cancer cells and plays a role in their growth and survival. By breaking down BCL6, ARV-393 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing MEDI5752 and AZD2936 with standard treatments in people with cancer. The people in this study have primary liver or biliary cancer, including biliary tract or gallbladder cancer, that spread or cannot be surgically removed (inoperable). In addition, they have not yet received treatment for the cancer.
Researchers want to see how well the drugs sapanisertib and serabelisib (PIKTOR) work when given together to treat endometrial cancer. The people in this study have endometrial cancer that has come back or grown after treatment. They also have genetic changes in the pathway that PIKTOR targets. These changes can cause resistance to chemotherapy drugs.
